期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中国南方冠心病介入治疗患者CYP2C19基因多态性分析 被引量：5

Cytochrome CYP2C19 Polymorphism in Southern Chinese Patients with Coronary Disease Undergoing Percutaneous Coronary Intervention
暂未订购
导出
摘要 目的研究中国南方冠心病介入治疗患者CYP2C19基因多态性的分布。方法选取确诊为冠心病并同意行冠状动脉支架术(PCI)治疗的患者112例,抽取外周血并通过提取基因组DNA检测CYP2C19的基因型。结果在112例检测标本中,CYP2C19纯合子强代谢型(homEMs)、杂合子强代谢型(hetEMs)及弱代谢型(PMs)的发生率分别为40.2%、48.2%和11.6%。结论中国南方冠心病介入治疗患者中,弱代谢者的发生率低于中国汉族人总体发生率。 Objective To investigate distribution status of cytochrome CYP2C19 polymorphisms in Southern Chinese patients with coronary disease undergoing percutaneous coronary intervention（ PCI）. Methods We selected 112 patients who were diagnosed as coronary heart disease and agreed to receive PCI treatment,took patients＇ peripheral blood and extracted genomic DNA to determine the CYP2C19 genotype. Results The frequency of CYP2C19 homozygous extensive metabolisms（ homEMs）,heterozygous extensive metabolisms（ hetEMs） and poor metabolisms（ PMs） in the 112 cases with coronary disease undergoing PCI was respectively 40. 2% 、48. 2% and11. 6%. Conclusion In Southern Chinese patients with PCI,the frequency of CYP2C19 poor metabolisms is lower than its frequency of Chinese population.
作者 陆冬晓 陆东风 褚亚娟
机构地区 广州医科大学附属第一医院心内科
出处 《血栓与止血学》 2014年第3期111-113,共3页 Chinese Journal of Thrombosis and Hemostasis
关键词 CYP2C19基因多态性 氯吡格雷抵抗 冠心病介入治疗 支架内血栓 CYP2C19 polymorphisms Clopidogrel resistance After percutaneous coronary inter-vention Stent thrombosis.
分类号 R553.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献12

  • 1TOLLESON TR, NEWBY LK, HARRINGTON RA, et al. Frequency of stent thrombosis after acute coronary syndromes [ J ]. Am J Cardiol, 2003,92(3) :302-333.
  • 2SIMON T, VERSTUYFT C, PHARM D. Genetic determinants of re- sponse to clopidogrel and cardiovascular events [ J ]. N Engl J Med, 2009,360(4) :363-375.
  • 3FRERE C, CUISET T, MORANGE PE. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome [ J]. Am J Cardiol, 2008,101 ( 8 ) : 1088- 1093.
  • 4KING SB, SMITH SC, HIRSHFELD JW, et al. 2005 WRITING COMMITTEE MEMBERS, Feldman TE, Kern MJ, O1Neill WW, et al, 2007 Focused Update of the ACC/AHA/SCAI2005 Guideline Update for Percutaneous Coronary Intervention : a report of the American Col- lege of Cardiology/American Heart Association Task Force on Prac- tice Guidelines:2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Commit- tee. Circulation ,2008,117:261-295.
  • 5KAZUI M,NISHIYA Y,ISHIZUKA T, et al. Identification of the hu- man cytoehrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabo- lite[J]. Drug Metab Dispos,2010,38:92-99.
  • 6NGUYEN TA, DIODATI JG, PHARANDC. Resistance to clopi- dogrel : a review of the evidence [ J ]. J Am Coil Cardiol, 2005, 45 : 1157-1164.
  • 7HULOT JS, BURA A, VILLARD E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [ J ]. Blood, 2006,108 ( 7 ) : 2244- 2247.
  • 8SIMON T, VERSTUYFTC, MARY-KRAUSE M,et al; French Regis- try of Acute ST- Elevation and Non- ST- Elevation Myocardial Infarc- tion ( FAST- MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events[ J]. N Engl J Med,2009,360: 363-375.
  • 9SIBBING D, STEGHERR J, LATZ W, et al. CytochromeP450 2C19 loss of function polymorphism and stent thrombosis following percu- tanenus coronary intervention[ J]. Eur Heart J,2009,30:916-922.
  • 10FONTANA P, SENOUF D, MACH F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and in- fluence of the cytochrome P450 2C19 * 2 allele on clopidogrel respon- siveness[ J]. Thromb Res ,2008 ,121 (4) :463-468.

同被引文献62

  • 1邱林,王智,龚艳君,洪涛,杨帆,霍勇.冠心病患者冠状动脉药物洗脱支架植入前后高敏C反应蛋白和白细胞介素6的变化[J].中国动脉硬化杂志,2015,23(1):59-63. 被引量：18
  • 2Yousef AM, Bulatova NR, Newman W, et al. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYIA4, CYP3AS, CYP2C9 and CYP2C19) in the Jordanian population [J ]. Mol BM Rep, 2012,39(10) :9423 -9433.
  • 3Chen HF, Shi XS. Research proess of cytochrome P450C19 [ J ]. China Cancer, 2006,15 (2) : 116 - 119.
  • 4Karunakaran A, Judge H, Morton A, et al. Cytocbrume P450 2C19 loss - of - function genetic variants but not paraoxonase - 1 activity modulate P2Y12 blockade in response to clopidogrel - therapy [J]. J Am Coil Cardiol, 2011,58(20) :IM5.
  • 5Kazui M, Nishiya Y, Ishizuka T, et al. Identication of the hu- man cytochrome 17450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite [ J]. Drug Metab Dispos, 2010,38 ( 1 ) :92 - 99.
  • 6Simon T, Bhatt DL, Bergougnan L, et al. Genetic polymor- phisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects [ J ]. Clin Pharmacol Ther, 2011,90 (2) :287 - 295.
  • 7Mo SL, Liu YH, Duan W, et al. Substrate specicity, regulation, and polymorphism of human cytochrome P450 2B6 [ J]. Curr Drug Metab, 2009,10(7) :730 -753.
  • 8经皮冠状动脉介入治疗指南（2009）[J].中华心血管病杂志,2009,37(1):4-25. 被引量：554
  • 9杨蓉,吴方.氯吡格雷抵抗的研究进展[J].国际内科学杂志,2009,36(7):428-431. 被引量：21
  • 10顾连云,赵萍.CYP2C19基因多态性在江苏及其周边地区汉族人群的调查研究[J].实用临床医药杂志,2011,15(1):125-128. 被引量：20

引证文献5

二级引证文献29

血栓与止血学
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部